

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Katja C. Weisel,¹ Meletios A. Dimopoulos,² Philippe Moreau,³ Martha Q. Lacy,⁴ Kevin W. Song,⁵ Michel Delforge,⁶ Lionel Karlin,⁷ Hartmut Goldschmidt,⁸ Anne Banos,⁹ Albert Oriol,¹⁰ Adrian Alegre,¹¹ Christine Chen,¹² Michele Cavo,¹³ Laurent Garderet,¹⁴ Valentina Ivanova,¹⁵ Joaquin Martinez-Lopez,¹⁶ Stefan Knop,¹⁷ Xin Yu,¹⁸ Kevin Hong,¹⁸ Lars Sternas,¹⁸ Christian Jacques,¹⁸ Mohamed H. Zaki,¹⁸ and Jesus San Miguel¹⁹

¹Hematology and Oncology, Department of Medicine, University Hospital Tübingen, Germany; ²National and Kapodistrian University of Athens, Greece; ³Hematology, University Hospital Hôtel-Dieu, Nantes, France; ⁴Division of Hematology, Mayo Clinic, Rochester, MN, USA; ⁵Vancouver General Hospital, BC, Canada; ⁶Department of Hematology, University Hospitals Leuven, Belgium; ⁷Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France; ⁸Universitäts Klinikum Heidelberg, Germany; ⁹Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France; ¹⁰Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Barcelona, Spain; ¹¹Hospital Universitario La Princesa, Madrid, Spain; ¹²Princess Margaret Hospital, Toronto, ON, Canada; ¹³Bologna University School of Medicine, Institute of Hematology and Medical Oncology, Bologna, Italy; ¹⁴Hôpital Saint-Antoine, Paris, France; ¹⁵GUZ Moscow City Clinical Hospital S. P. Botkin, Moscow, Russia; ¹⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁷Hematology and Oncology, Würzburg University Medical Center, Würzburg, Germany; ¹⁸Celgene Corporation, Summit, NJ, USA; and ¹⁹Clínica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.137083

Received: December 15, 2015.

Accepted: April 12, 2016.

Pre-published: April 14, 2016.

Correspondence: katja.weisel@med.uni-tuebingen.de

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma


Katja C. Weisel,¹ Meletios A. Dimopoulos,² Philippe Moreau,³ Martha Q. Lacy,⁴ Kevin W. Song,⁵ Michel Delforge,⁶ Lionel Karlin,⁷ Hartmut Goldschmidt,⁸ Anne Banos,⁹ Albert Oriol,¹⁰ Adrian Alegre,¹¹ Christine Chen,¹² Michele Cavo,¹³ Laurent Garderet,¹⁴ Valentina Ivanova,¹⁵ Joaquin Martinez-Lopez,¹⁶ Stefan Knop,¹⁷ Xin Yu,¹⁸ Kevin Hong,¹⁸ Lars Sternas,¹⁸ Christian Jacques,¹⁸ Mohamed H. Zaki,¹⁸ and Jesus San Miguel¹⁹

¹Hematology and Oncology, Department of Medicine, University Hospital Tübingen, Tübingen, Germany; ²National and Kapodistrian University of Athens, Athens, Greece; ³Hematology, University Hospital Hôtel-Dieu, Nantes, France; ⁴Division of Hematology, Mayo Clinic, Rochester, MN, USA; ⁵Vancouver General Hospital, Vancouver, BC, Canada; ⁶Department of Hematology, University Hospitals Leuven, Leuven, Belgium; ⁷Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France; ⁸Universitäts Klinikum Heidelberg, Heidelberg, Germany; ⁹Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France; ¹⁰Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Barcelona, Spain; ¹¹Hospital Universitario La Princesa, Madrid, Spain; ¹²Princess Margaret Hospital, Toronto, Ontario, Canada; ¹³Bologna University School of Medicine, Institute of Hematology and Medical Oncology, Bologna, Italy; ¹⁴Hôpital Saint-Antoine, Paris, France; ¹⁵GUZ Moscow City Clinical Hospital S. P. Botkin, Moscow, Russia; ¹⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁷Hematology and Oncology, Würzburg University Medical Center, Würzburg, Germany; ¹⁸Celgene Corporation, Summit, NJ, USA; ¹⁹Clínica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain

Supplementary Results

POM + LoDEX significantly improved ORR versus HiDEX in patients with baseline CrCl ≥ 30 - < 60 mL/min (28% vs 11%; $P = .014$) and in patients with baseline CrCl ≥ 60 mL/min (34% vs 12%; $P < .001$) (Table 2). Note, the percentages in Table 2 may not add to 100% due to rounding.

Supplemental Figure 1. Patient disposition and analysis populations as of September 1, 2013 data cutoff.



CrCl, creatinine clearance; HiDEX, high-dose dexamethasone; LoDEX, low-dose dexamethasone; POM, pomalidomide; Tx, treatment.